Your Search Returned 101 tagged news reports
Two years ago, the US Attorney in New York opened an investigation into Cephalon, which was since bought by Teva Pharmaceuticals, over allegations of off-label marketing of its Treanda medication for treating chronic lymphocytic leukemia ( back story
Tags:
MultiGeneAngio, a cell-based therapy for the treatment of peripheral artery disease and blocked arteries in the leg...MultiGeneAngio, in exchange for commercial rights and an option to make an additional investment in the company or even acquire it
Tags:
G The present transaction concerns the over-the-counter products that Teva acquired from Cephalon in 2011...The Commission concluded that the transaction would not raise competition concerns because it would not significantly alter the market
Tags:
But even FDA defenders are shocked by reports this week of an institutionalized FDA spying program on its own scientists, lawmakers, reporters and academics that included an enemies list of "actors" and collaborators. The paranoid and retaliatory
Tags:
Teva's share price has lost 40% of its value over the past 18 months, so is it a buy opportunity?...If this is correct, then why has Teva's share price lost more than 40% of its value over the past 18 months?...There are numerous reasons for the fall
Tags:
Four years after Cephalon paid $425 million to settle charges that its Actiq pain medication for cancer patients was marketed for unapproved uses, Travelers Insurance is demanding a $17.4 million payment to cover reimbursement costs for its insured
Tags:
Teva's share price has lost 40% of its value over the past 18 months, so is it a buy opportunity?...If this is correct, then why has Teva's share price lost more than 40% of its value over the past 18 months?...There are numerous reasons for the fall
Tags:
The two patents, owned by Aptalis and licensed to Cephalon, will expire in 2023 and 2025. Aptalis president John Fraher said, "Aptalis Pharmaceutical Technologies endeavors to offer to our partners the most effective patent protection possible of our
Tags:
Despite settling a litigation with innovator Cephalon, Ranbaxy has not been able to launch the generic version of Provigil (modafinil) in the US, casting a shadow on its ability to monetise first-to-file (FTF) opportunities. Provigil (modafinil) is a
Tags:
Teva's share price has lost 40% of its value over the past 18 months, so is it a buy opportunity?...If this is correct, then why has Teva's share price lost more than 40% of its value over the past 18 months?...There are numerous reasons for the fall
Tags: